SCHEMBL3660432

SCHEMBL3660432

Brc1cncc(-c2ccnc(-c3ccccn3)n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 9/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
TP53 P04637 5/20 0.46
NPC1 O15118 4/20 0.46
RAB9A P51151 4/20 0.46
PKM P14618 4/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
TSHR P16473 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PPP1CA P62136 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP2A6 P11509 1/20 0.42
GABRA1 P14867 1/20 0.41
GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121006 0.86 CYP2A6 (0.56) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL4179017 0.80 GRM5 (0.71) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL3754688 0.79 GRM5 (0.42) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL4197856 0.76 GRM5 (0.61) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL9486704 0.76 KDM4E (0.59) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL5799279 0.75 PTK2 (0.52) KDM4EALDH1A1NPC1RAB9ASMN1; SMN2
SCHEMBL6625981 0.74 GRM5 (0.48) GRM5KDM4EALDH1A1TSHRMAPT
SCHEMBL3663765 0.73 CCR1 (0.40) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL2462770 0.73 CYP2A6 (0.67) GRM5KDM4EALDH1A1TP53NPC1
SCHEMBL776048 0.73 KDM4E (0.67) GRM5KDM4EALDH1A1TP53NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231642-B1 PYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-10-23 EP disclosed
US-8431578-B2 Organic compounds NOVARTIS AG (CH) 2013-04-30 US disclosed
US-20100298337-A1 Organic Compounds NOVARTIS AG (CH) 2010-11-25 US disclosed
EP-2231642-A1 PYRIMIDINES AS KINASE INHIBITORS Novartis AG (CH) 2010-09-29 EP disclosed
WO-2009087224-A1 PYRIMIDINES AS KINASE INHIBITORS NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298337-A1 Organic Compounds CYP11B2, TNNT2, CPT1B GRM5 4496/4885KDM4E 3699/4885ALDH1A1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.